Urinary tract infection (UTI treatment) is the
infection of the lower or upper urinary tract due to bacteria such as
Escherichia coli, Staphylococcus saprophyticus etc. The symptoms of UTI
treatment are pain with urination, frequent urination and urination feeling
despite having an empty bladder. The market driving factors for UTI treatment
are female anatomy, sexual intercourse, diabetes, obesity etc. Due to the
complications of female anatomy UTI treatment affects females more than males
with the World Health Organization (WHO) estimating that approximately 50 % of
women suffer from UTI treatment at some point of time in their lives resulting
in more than 1 million hospitalizations per year. It has further been stated
that 1% of boys and 3-8% of girls are diagnosed with UTI treatment and the
annual cost of UTI treatment infections treatment to be greater than $1
billion.
The Global urinary tract infection (UTI treatment) drugs market
is growing due to factors such as rise in hospital borne infections (nosocomial
infections), child birth, old age, obesity, growing health awareness especially
about women health etc. However the fastest growth has been registered due to
rising use of catheters (catheter associated UTI treatment).
The market constraints include growing drug resistance, unmet
clinical needs, increasing incidence of chronic diseases resulting in chronic
catheter use and low immunity etc. Taking all these factors into consideration,
the Global UTI treatment drugs market will approximately reach to $ 9.89
billion in 2023 from $ 8 billion in 2016 growing at a CAGR of 3.6%.
Key players of Global UTI treatment Market
·
Bayer AG
·
Novartis AG
·
Pfizer Inc.
·
F. Hoffmann-La Roche Ltd
·
AstraZeneca
·
Cipla Inc.
·
Dr. Reddy’s Laboratories Ltd.
·
Johnson & Johnson GlaxoSmithKline
Segmentation
The Global UTI treatment Market
is segmented on the basis of drug class which comprises of quinolones,
aminoglycosides, β-lactam, azoles and others. On the basis of clinical
indications this market is segmented into urethritis, cystitis, and
pyelonephritis. On the basis of end users the market is segmented into
hospitals and self-administered.
Regional analysis
U.S. accounts for the largest
market share of the global UTI treatment market followed by Europe. However
Europe has a greater hospitalization rate than the U.S. despite the U.S. having
a large spending on healthcare. The regulatory changes in the U.S. such as
implementation of Affordable Care Act and Hospital Readmissions Reduction
Program coupled with Medicare initiative to penalize unnecessary patient
readmissions is expected to take a toll on the U.S UTI treatment market. Asia
pacific will be the fastest growing market and the growth will be led by China,
and India as these nations have huge population and the low cost of UTI
treatment drugs.
Detailed
Table of Contents:
1
Introduction
1.1 Definition
1.2
Scope Of Study
1.3
Research Objective
1.4
Assumptions & Limitations
1.5
Market Structure:
2
Research Methodology
2.1
Research Process
2.2
Primary Research
2.3
Secondary Research
3
Market Dynamics
3.1
Drivers
3.2
Restraints
3.3
Opportunities
3.4
Challenges
3.5
Macroeconomic Indicators
4
Market Factor Analysis
4.1
Porter’s Five Forces Model
4.1.1
Bargaining Power Of Suppliers
4.1.2
Bargaining Power Of Customer
4.1.3
Intensity Of Competitor’s
4.1.4
Threat Of New Entrants
...Continued
About US:
Market Research
Future (MRFR), enable customers to unravel the complexity of various industries
through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw
Research Reports (3R), Continuous-Feed Research (CFR), and Market Research
& Consulting Services.
Contact Us:
Market Research
Future
Office No. 528,
Amanora Chambers
Magarpatta Road,
Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845
9312
Email:
sales@marketresearchfuture.com
No comments:
Post a Comment